Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation
Source abstract
Abstract
Anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, therapy has significantly improved the clinical outcomes of patients with colorectal cancer, but the response to cetuximab can vary widely among individuals. We thus need strategies for predicting the response to this therapy. However, the current methods are unsatisfactory in their predictive power. Cetuximab can promote the internalization and degradation of EGFR, and its therapeutic efficacy is significantly correlated with the degree of EGFR degradation. Here, we present a new approach to predict the response to anti-EGFR therapy, cetuximab by evaluating the degree of EGFR internalization and degradation of colorectal cancer cells in vitro and in vivo. Our newly developed fluorogenic cetuximab-conjugated probe (Cetux-probe) was confirmed to undergo EGFR binding, internalization, and lysosomal degradation to yield fluorescence activation; it thus shares the action mechanism by which cetuximab exerts its anti-tumor effects. Cetux-probe-activated fluorescence could be used to gauge EGFR degradation and showed a strong linear correlation with the cytotoxicity of cetuximab in colorectal cancer cells and tumor-bearing mice. The predictive ability of Cetux-probe-activated fluorescence was much higher than those of EGFR expression or KRAS mutation status. The Cetux-probes may become useful tools for predicting the response to cetuximab therapy by assessing EGFR degradation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Colorectal Cancer Treatments and Studies · HER2/EGFR in Cancer Research · Chronic Lymphocytic Leukemia Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. The quest to overcome resistance to EGFR-targeted therapies in cancer10.1038/nm.3388 ↗
2. The latest Battles between EGFR monoclonal antibodies and resistant tumor cells
3. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer10.1056/NEJMoa033025 ↗
4. Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor10.1200/JCO.2004.10.182 ↗
5. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry10.1200/JCO.2005.08.037 ↗
6. American society of clinical oncology Provisional clinical opinion: testing for KRAS Gene mutations in patients with metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy10.1200/JCO.2009.21.9170 ↗
7. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent Predictors in metastatic colorectal cancer patients treated with cetuximab
8. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab10.1093/annonc/mdm496 ↗
9. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer10.1158/0008-5472.CAN-06-0191 ↗
10. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer10.1038/sj.onc.1210381 ↗
11. Antibody-incorporated Nanomedicines for cancer therapy10.1002/adma.202109210 ↗
12. Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma10.1002/ijc.22370 ↗
13. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation10.1073/pnas.83.11.3825 ↗
14. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly10.1016/S0021-9258(20)89475-7 ↗
15. EGFR Downregulation after anti-EGFR therapy predicts the Antitumor effect in colorectal cancer10.1158/1541-7786.MCR-16-0383 ↗
16. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface
17. PROTAC targeted protein degraders: the past is prologue10.1038/s41573-021-00371-6 ↗
18. Nano-LYTACs for degradation of membrane proteins and inhibition of CD24/siglec-10 signaling pathway10.1002/advs.202300288 ↗
19. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations10.1074/jbc.M607958200 ↗
20. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy10.1158/0008-5472.CAN-09-1417 ↗
21. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface
22. Cetuximab/C225-Induced intracellular trafficking of epidermal growth factor receptor10.1158/0008-5472.CAN-09-0049 ↗
23. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth10.1158/1078-0432.CCR-14-2491 ↗
24. Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation10.1038/s41598-019-57153-9 ↗
25. Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug10.1016/j.jconrel.2020.08.046 ↗
26. In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe10.1016/j.biomaterials.2013.08.026 ↗
27. Cathepsin B-specific metabolic Precursor for in vivo tumor-specific fluorescence imaging10.1002/anie.201608504 ↗
28. The effect of bafilomycin A1 and protease inhibitors on the degradation and recycling of a Class 5-mutant LDLR10.1093/abbs/gmp008 ↗
29. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass10.1046/j.1432-1327.1999.00582.x ↗
30. Z-FA-fmk inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer Retinoid-related molecules induce Apoptosis via the intrinsic Pathway1
31. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements10.2165/00003088-199631040-00003 ↗
32. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B110.1083/jcb.63.2.430 ↗
33. ZNRF1 mediates epidermal growth factor receptor Ubiquitination to control receptor lysosomal trafficking and degradation10.3389/fcell.2021.642625 ↗
34. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
35. Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy10.1159/000373998 ↗
36. An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression10.1158/0008-5472.CAN-09-0986 ↗
37. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer10.1158/1078-0432.CCR-08-2635 ↗
38. Antibody-drug-conjugate therapy for Hematological cancers: matching cell Biology with clinical benefit10.1002/adfm.202100032 ↗
39. Antibody drug conjugate: the “biological missile” for targeted cancer therapy10.1038/s41392-022-00947-7 ↗
40. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers10.3389/fmolb.2022.847835 ↗
41. Enzyme-engineered conjugated Polymer Nanoplatform for activatable companion diagnostics and multistage Augmented synergistic therapy10.1002/adma.202200062 ↗
42. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab10.1002/ijc.31274 ↗
43. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple-negative breast cancer cell lines
44. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation10.1038/s41589-021-00770-1 ↗
45. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer10.1073/pnas.1521738113 ↗
46. Semiconducting Polymer Nanoparticles with surface-mimicking protein secondary structure as lysosome-targeting chimaeras for self-synergistic cancer immunotherapy10.1002/adma.202203309 ↗
47. Targeted protein degradation Technology and Nanomedicine: powerful Allies against cancer10.1002/smll.202207778 ↗